Czech Republic Plans to Reduce Tobacco Harm with Nicotine Pouches

Jul.01.2022
Czech Republic Plans to Reduce Tobacco Harm with Nicotine Pouches
Czech Republic to implement a tobacco harm reduction strategy including the use of nicotine pouches, as local leadership attitudes change.

Due to a change in the mentality of local leaders, the Czech Republic will be implementing a strategy aimed at reducing the harm caused by tobacco, which includes the use of nicotine pouches. According to Ondřej Jakob, a spokesperson for the Czech Ministry of Health, a new action plan is currently being discussed and is expected to be implemented in the near future.

 

This issue has yet to be resolved. A new law is being prepared for nicotine pouches to define their composition, appearance, quality, characteristics, and other parameters, in order to minimize their adverse effects on human health." Jakob explained. The new law is expected to consider various factors that need to be taken into account. He said, "At this point, we anticipate debating a new action plan that should set the direction for the next three years, including tobacco addiction.

 

According to ECigIntelligence, successfully implementing harm reduction in the country's next three-year action plan could also promote other safer alternatives, such as electronic cigarettes and nasal snuff. Jakob discussed these products, stating that "electronic cigarettes and heated tobacco products are both controversial.

 

We believe that, in the future, new products should be designed with flavors that mask the unpleasant taste of nicotine while still adhering to harm reduction principles. However, they should be limited as much as possible to attract as few people as possible, especially young people, to avoid creating another batch of nicotine addicts.

 

The threat to teenagers, including risks to their health and the emergence of new addictions, has yet to be resolved and this may also apply to current non-smokers. For this reason, the Czech Republic is currently discussing this issue," he added.

 

The European Union is still spreading the "debunked theory".

 

Meanwhile, the EU Health and Food Safety Commissioner, Stella Kyriakides, questioned the effectiveness of e-cigarettes as a smoking cessation aid and even claimed that they are a gateway to smoking in another statement spreading misinformation about e-cigarettes.

 

Michael Landl, Director of the World Vapers' Alliance (WVA), expressed concern that the European Commission is still disregarding scientific evidence on e-cigarettes. He stated that it is alarming that the Commission continues to promote outdated and debunked theories on e-cigarettes, and systematically ignores vast amounts of scientific evidence that demonstrates their benefits, not to mention the firsthand experiences of millions of e-cigarette users. Compared to traditional therapies like gum or patches, e-cigarettes are 95% less harmful than smoking and a more effective method for quitting. The Commission's approach to e-cigarettes will only result in loss of life.

 

“Overall, it is known that both smokeless and novel tobacco and related products contain nicotine, a toxic and highly addictive substance known to be harmful to health - enhancing nicotine addiction. This is why these products are regulated and, as far as oral tobacco is concerned, banned by the European Union,” the statement concluded.

 

This article is compiled from third-party information sources, and the copyright of the compiled information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
According to recent LinkedIn posts from people at VAPORESSO, SMOORE and a German distribution partner, vape brand DOJO will begin rolling out a new global brand identity on September 1, 2026, led by a redesigned handwritten logo. The new visual system will be gradually applied across product packaging, marketing materials and digital assets over the following months. Fabio Corsaro, Head of Marketing and Purchasing at MG Wesel GmbH, said the rebrand was related to trademark issues, but that explanation has not been publicly confirmed by DOJO, VAPORESSO or SMOORE. DOJO is currently promoting its Blast X product in Germany.
Aug.31
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
Philip Morris Italia Invests €1 Million to Upgrade Retail Network, Supporting 45,000 Tobacco Shops in Smoke-Free Shift
Philip Morris Italia Invests €1 Million to Upgrade Retail Network, Supporting 45,000 Tobacco Shops in Smoke-Free Shift
Philip Morris Italia has launched the Trade Academy program, investing €1 million to provide training and development support for approximately 45,000 tobacco retailers in Italy. The initiative aims to strengthen retailers’ capabilities in heated tobacco products, digital tools and consumer services. The move reflects how nicotine companies are increasingly investing in retail networks and frontline capabilities as new nicotine products become more important in the market.
Jul.28
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19